Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib + Eribulin in Pretreated Advanced PIK3CA-mutated TNBC
NCT07441512Phase 2Not yet recruiting
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of inavolisib in triple-negative breast cancer (TNBC), sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd.. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
inavolisib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07441512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441512.